Switzerland-based Dishman Carbogen Amcis’ subsidiary, Carbogen Amcis, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the signing of a co-investment agreement with one of its key European customers. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer's commercial product and follows a previous investment of CHF 6 million.

The co-investment totals CHF 4 million and will be focussed on expanding capacities to support the market introduction of the customer's lead compound. The investment at the CARBOGEN AMCIS AG. Neuland location includes the addition of a medium pressure chromatography column (200L),a preparative 20 cm HPLC system and short path distillation equipment.

"We are committed to providing our customers with the best technologies and this investment willallow our client to benefit from state-of-the-art equipment that enables expanded manufacturing capacity to commercialization scale-up, and getting a much-needed drug to patients," said Stephan Fritschi, VP operations, CARBOGEN AMCIS AG.

This agreement follows an earlier CHF 6 million investment made in 2017 by the same customer at the Carbogen Amcis Neuland location.

The collaboration between the two companies spans more than 10 years and started during the project's pre-clinical development stage.

"We have supported our client from the early stages of preclinical development all the way through to routine commercial manufacture. We are proud to be part of our customer's successful journey towards product commercialization and this co-investment is the latest milestone in our long-standing partnership," said Pascal Villemagne, VP sales and marketing, CARBOGEN AMCIS AG.

The equipment is expected to be ready for production by Q1 2023.